About
Designing Tests That Predict Your Risk of Developing Cancer
Proteocyte is developing a platform of solutions to predict a patient’s risk of developing cancer. Our platform identifies specific protein biomarkers that operate in combination with proprietary algorithms, advanced imaging and digital pathology enabling us to predict an individuals’ probability of non-cancerous lesions progressing to invasive cancer.
Founded in 2011, Proteocyte identified the need to provide healthcare professionals with more objective and quantifiable information that would significantly improve the outcome for their patients.
Proteocyte’s first product, Straticyte™, is a test that predicts the progression of pre-malignant lesions to invasive oral cancer. Straticyte enables healthcare professionals to customize patient management/treatment, improving outcomes for patients at risk for developing oral cancer, while reassuring those patients who have minimal to no risk of disease progression.
Our Team

Steven Arless
Executive Chairman

Mark Hammar
Chief Executive Officer

Anthony Morlandt
Chief Medical Officer - USA

Barrie Renick
Chief Medical Officer - Canada

John Jordan
Chief Financial Officer

Ken Pritzker
Medical Director

David Mock
Medical Advisor

Jason Hwang
Principal Scientist & Lab Manager
Board of Directors

Steven Arless
Executive Chairman

Carlo Sistilli
Director

Anthony Morlandt
Director

Barrie Renick
Director

John Jordan
Director
Clinical Advisory Board

Eric Dierks
MD, DMD, FACS, FACD, FRCS(Ed)

Rui Fernandes
MD, DMD, FACS, FRCS

Deepak Kademani
MD, DMD, FACS

Diana Lin
MD

James Melville
DDS, FACS

Ian Witterick
MD, MSc, FRCSC

Simon Young
DDS, MD, PhD, FACS